Clinical Data, Inc. (NASDAQ:CLDA) reported the gain of 5.48% and closed at $26.76 whereas overall traded volume stood at 1.05 million shares for the day. Its outstanding share...(
read more)
Jeremy Richards
Somaxon Pharmaceuticals (SOMX) looks to be an exceptional bargain buy for new investors given analyst opinions along with zero debt and forward sales expectations. I believe SOMX is...(
read more)
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Somaxon and Procter & Gamble (NYSE: PG) have entered into a co-promotion agreement for Silenor(R) (doxepin), a newly-approved...(
read more)